ADVERSE REACTIONS SECTION.

6 ADVERSE REACTIONS. Hypersensitivity reactions: Hypersensitivity reactions occurring approximately 2% of patients and include life-threatening anaphylactic reactions with respiratory distress, shock, angioedema, urticaria, pruritus. death has been reported following IV administration of similar compound (6). To report SUSPECTED ADVERSE REACTIONS, contact U.S. Surgical at 1-800-522-0263 option and website or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Postmarketing Experience. Hypersensitivity Reactions: Case series report an overall incidence of hypersensitivity reactions in approximately 2% of patients. Life-threatening anaphylactic reactions have occurred. Manifestations include respiratory distress, shock, angioedema, urticaria, pruritus. death has been reported following administration of similar compound employed to estimate the depth of severe burn. Reactions are more likely to occur in patients with personal or family history of bronchial asthma, significant allergies, drug reactions or previous reactions to triphenylmethane dyes [see Warnings and Precautions (5)]. Laboratory tests: Lymphazurin 1% interferes with measurements of oxygen saturation by pulse oximetry and of methemoglobin by gas analyzer [see Warnings and Precautions (5)]. Skin: transient or long-term (tattooing) blue coloration.

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Lymphazurin 1%. Reproduction studies in animals have not been conducted and, therefore, it is unknown if problem concerning mutagenesis or impairment of fertility in either males or females exists.

CLINICAL PHARMACOLOGY SECTION.

12 CLINICAL PHARMACOLOGY. 12.2 Pharmacodynamics. Following subcutaneous administration, Lymphazurin 1% binds to serum proteins and is picked up by the lymphatic vessels. Thus, the lymphatic vessels are delineated by the blue dye. 12.3 Pharmacokinetics. Up to 10% of the subcutaneously administered dose of Lymphazurin 1% is excreted unchanged in the urine in 24 hours in human.

CONTRAINDICATIONS SECTION.

4 CONTRAINDICATIONS. Lymphazurin(TM) 1% (isosulfan blue) is contraindicated in those individuals with known hypersensitivity to triphenylmethane or related compounds. Hypersensitivity to triphenylmethane or related compounds (4).

DESCRIPTION SECTION.

11 DESCRIPTION. The chemical name of Lymphazurin 1% (isosulfan blue) is N-[4-[[4-(diethylamino)phenyl] (2,5-disulfophenyl) methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylehananamunium hydroxide, inner salt, sodium salt. Its structural formula is: Lymphazurin 1% is sterile aqueous solution for subcutaneous administration. Phosphate buffer in sterile, pyrogen free water is added in sufficient quantity to yield final pH of 6.8-7.4. Each ml of solution contains 10 mg Isosulfan blue, 6.6 mg sodium monohydrogen phosphate and 2.7 mg potassium dihydrogen phosphate. The solution contains no preservative. Lymphazurin 1% is contrast agent for the delineation of lymphatic vessels. Chemical Structure.

DOSAGE & ADMINISTRATION SECTION.

2 DOSAGE AND ADMINISTRATION. Lymphazurin(TM) 1% is to be administered subcutaneously, one-half (1/2) ml into three (3) interdigital spaces of each extremity per study. maximum dose of ml (30 mg) isosulfan blue is, therefore, injected (2.1). 2.1 Subcutaneous administration. Lymphazurin(TM) 1% is to be administered subcutaneously, one-half (1/2) ml into three (3) interdigital spaces of each extremity per study. maximum dose of ml (30 mg) isosulfan blue is, therefore, injected.

DOSAGE FORMS & STRENGTHS SECTION.

3 DOSAGE FORMS AND STRENGTHS. 1% aqueous solution (isosulfan blue) 1% aqueous solution (isosulfan blue).

DRUG INTERACTIONS SECTION.

7 DRUG INTERACTIONS. No Drug Interactions have been identified with Lymphazurin 1%. No drug interactions have been identified for Lymphazurin 1% (7).

HOW SUPPLIED SECTION.

16 HOW SUPPLIED/STORAGE AND HANDLING. Lymphazurin 1% is supplied as 5 ml single dose vial, 1% aqueous solution in phosphate buffer prepared by appropriate manufacturing to be sterile and pyrogen-free.

INDICATIONS & USAGE SECTION.

1 INDICATIONS AND USAGE . Lymphazurin(TM) 1% (isosulfan blue) upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities (1.1). 1.1 Lymphatic Vessel Delineation. Lymphazuirn(TM) 1% (isosulfan blue) upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities.

INFORMATION FOR PATIENTS SECTION.

17 PATIENT COUNSELING INFORMATION. Inform patients that urine color may be blue for 24 hours following administration of Lymphazurin 1%.

NONCLINICAL TOXICOLOGY SECTION.

13 NONCLINICAL TOXICOLOGY. 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility. Long-term studies in animals have not been performed to evaluate the carcinogenic potential of Lymphazurin 1%. Reproduction studies in animals have not been conducted and, therefore, it is unknown if problem concerning mutagenesis or impairment of fertility in either males or females exists. 13.2 Teratogenic Effects. Pregnancy Category C. Animal reproduction studies have not been conducted with Lymphazurin 1%. It is not known whether Lymphazurin 1% can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Lymphazurin 1% should be given to pregnant woman only if clearly needed.

NURSING MOTHERS SECTION.

8.3 Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lymphazurin(TM) 1% (isosulfan blue) is administered to nursing mother.

OVERDOSAGE SECTION.

10 OVERDOSAGE. Do not exceed indicated recommended dosage as overdosage levels have not been identified for Lymphazurin 1%.

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL.

PRINCIPAL DISPLAY PANEL. D.I.N. 00592358NDC 63261-250-21 LYM-100LYMPHAZURIN 1%(isosulfan blue) Single Dose Vial ml.Mfd. for United States Surgical, division ofTyco Healthcare Group LP,Norwalk, CT 06856 USA.by Ben Venue Labs, Inc., Bedford, OH 44146 USADistributed in Canada by: Tyco HealthcareMontreal, QuebecCanada, H9R 5H8. Principal Display Panel.

PEDIATRIC USE SECTION.

8.4 Pediatric Use. Safety and effectiveness of Lymphazurin(TM) 1% (isosulfan blue) in children have not been established.

PHARMACODYNAMICS SECTION.

12.2 Pharmacodynamics. Following subcutaneous administration, Lymphazurin 1% binds to serum proteins and is picked up by the lymphatic vessels. Thus, the lymphatic vessels are delineated by the blue dye.

PHARMACOKINETICS SECTION.

12.3 Pharmacokinetics. Up to 10% of the subcutaneously administered dose of Lymphazurin 1% is excreted unchanged in the urine in 24 hours in human.

RECENT MAJOR CHANGES SECTION.

RECENT MAJOR CHANGES. Warnings and Precautions, Interference with Oxygen Saturation and Methemoglobin Measurements (5.3). 10/2007.

SPL UNCLASSIFIED SECTION.

1.1 Lymphatic Vessel Delineation. Lymphazuirn(TM) 1% (isosulfan blue) upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities.

TERATOGENIC EFFECTS SECTION.

13.2 Teratogenic Effects. Pregnancy Category C. Animal reproduction studies have not been conducted with Lymphazurin 1%. It is not known whether Lymphazurin 1% can cause fetal harm when administered to pregnant woman or can affect reproduction capacity. Lymphazurin 1% should be given to pregnant woman only if clearly needed.

USE IN SPECIFIC POPULATIONS SECTION.

8 USE IN SPECIFIC POPULATIONS. Caution should be exercised when Lymphazurin 1% is administered to nursing mothers (8.3).Safety and effectiveness of Lymphazurin 1% in children has not been established (8.4). Caution should be exercised when Lymphazurin 1% is administered to nursing mothers (8.3).. Safety and effectiveness of Lymphazurin 1% in children has not been established (8.4). 8.3 Nursing Mothers. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lymphazurin(TM) 1% (isosulfan blue) is administered to nursing mother. 8.4 Pediatric Use. Safety and effectiveness of Lymphazurin(TM) 1% (isosulfan blue) in children have not been established.

WARNINGS AND PRECAUTIONS SECTION.

5 WARNINGS AND PRECAUTIONS. Life-threatening anaphylactic reactions have occurred after Lymphazurin 1% administration. Monitor patients closely for at least 60 minutes after administration of Lymphazurin 1% (5.1).The admixture of Lymphazurin 1% with local anesthetics results in an immediate precipitation of 4-9% drug complex. Use separate syringe for anesthetics (5.2). Lymphazurin 1% interferes with measurements in peripheral blood pulse oximetry. Arterial blood gas analysis may be needed (5.3). Life-threatening anaphylactic reactions have occurred after Lymphazurin 1% administration. Monitor patients closely for at least 60 minutes after administration of Lymphazurin 1% (5.1).. The admixture of Lymphazurin 1% with local anesthetics results in an immediate precipitation of 4-9% drug complex. Use separate syringe for anesthetics (5.2). Lymphazurin 1% interferes with measurements in peripheral blood pulse oximetry. Arterial blood gas analysis may be needed (5.3). 5.1 Hypersensitivity Reactions. Life-threatening anaphylactic reactions (respiratory distress, shock, angioedema) have occurred after Lymphazurin 1% administration. Reactions are more likely to occur in patients with history of bronchial asthma, allergies, drug reactions or previous reactions to triphenylmethane dyes. Monitor patients closely for at least 60 minutes after administration of Lymphazurin 1%. Trained personnel should be available to administer emergency care including resuscitation. 5.2 Precipitation of Lymphazurin 1% by Lidocaine. The admixture of Lymphazurin 1% (with local anesthetics (i.e. lidocaine)) in the same syringe results in an immediate precipitation of - 9% drug complex. Use separate syringe to administer local anesthetic. 5.3 Interference with Oxygen Saturation and Methemoglobin Measurements. Lymphazurin 1% interferes with measurements of oxygen saturation in peripheral blood by pulse oximetry and can cause falsely low readings. The interference effect is maximal at 30 minutes and minimal generally by four hours after administration. Arterial blood gas analysis may be needed to verify decreased arterial partial pressure of oxygen. Lymphazurin 1% may also cause falsely elevated readings of methemoglobin by arterial blood gas analyzer. Therefore, co-oximetry may be needed to verify methemoglobin level.